Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Baking soda may cut kidney risk in type 1 diabetes

NCT ID NCT02502071

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking two doses of sodium bicarbonate (baking soda) over 24 hours could reduce uric acid crystals in the urine of adults with type 1 diabetes. Uric acid crystals can harm the kidneys, so lowering them might help prevent diabetic kidney disease. The trial involved 45 adults aged 18-45 with type 1 diabetes and measured changes in urine uric acid levels and crystal formation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sodium bicarbonate
What this could lead to
If it works, this could point toward a simple way to reduce kidney stone or kidney disease risk in people with type 1 diabetes.
What could go wrong
This is a small, short-term study with only 45 participants, so results may not apply widely. Sodium bicarbonate can cause side effects like stomach upset or electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

45 people

The number who actually took part.

Start date

Jan 2017

Finished

Aug 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (aged 18-45 years) with type 1 diabetes * Participants must be able to be fasting prior to study visit and give informed consent. Exclusion Criteria: * Non-type 1 diabetes * History of eGFR \<60 ml/min/1.73m2 or microalbuminuria or greater * History of hypocalcemia or at risk of hypocalcemia * Taking allopurinol or uric acid altering medications * Ketogenic diet * Ketonuria * Taking phosphorus binders (e.g. sevelamer) * Pregnant or breastfeeding * Taking the following medications which may interact with sodium bicarbonate (e.g. phentermine, pseudoephedrine, antifungal medication, cephalosporin antibiotics \[e.g. Keflex\], tetracycline antibiotics \[e.g. doxycycline\], steroids or lithium) * Taking SGLT-2 inhibitors * Taking blood pressure medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Barbara Davis Center for Diabetes

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.